HCC Panel
Early detection of Hepatocellular Carcinoma (HCC)
Validation StudyActive
Key Facts
Indication
Early detection of Hepatocellular Carcinoma (HCC)
Phase
Validation Study
Status
Active
Company
About Glycotest Diagnostics
Glycotest Diagnostics is a private, pre-revenue biotech focused on transforming liver disease diagnostics through its unique platform measuring abnormal fucosylation of serum glycoproteins. Its lead program is the HCC Panel, designed for early detection of hepatocellular carcinoma, which has shown promising preliminary clinical data outperforming the current standard (AFP) and is undergoing a 776-patient validation study. Backed by NetScientific and EMV Capital, Glycotest targets a large and growing global market of patients at risk from viral hepatitis and metabolic liver diseases like NASH, aiming to address a critical unmet need for sensitive, early-stage detection.
View full company profile